📬 Breast Cancer Intelligence Digest — Week 2026-W37

FDA granted accelerated approval to camizestrant plus a CDK4/6 inhibitor at ctDNA-detected ESR1 emergence, the EU approved first-line T-DXd plus pertuzumab, NSABP B-59/GeparDouze published a negative EFS result for neoadjuvant atezolizumab in TNBC, and phase 3 anbenitamab plus HB1801 raised tpCR to 62.4% in ERBB2-positive early breast cancer.

⚡ TL;DR

📄 Publications

Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trial. — Adding atezolizumab (773 patients) or placebo (777 patients) to neoadjuvant chemotherapy did not significantly improve event-free survival (HR 0.80, stratified log-rank P = 0.083, 4-year EFS difference 3.3%)
Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer: A Phase 3 Randomized Clinical Trial. — Among 521 patients, tpCR was 62.4% (164 patients) with anbenitamab plus HB1801 versus 51.2% (132 patients) with trastuzumab, pertuzumab and docetaxel; absolute difference 11.4 percentage points (95% CI 3.2 to 19.6), P = .004

🐦 Twitter / 🦋 Bluesky

FDA grants accelerated approval to camizestrant at ctDNA-detected ESR1 emergence — the first approval triggered by molecular, not radiographic, progression — FDA granted accelerated approval to camizestrant plus a CDK4/6 inhibitor for HR+/HER2- advanced breast cancer upon ESR1 mutation detected during AI plus CDK4/6i therapy, with mPFS 16 vs 9.2 months per label and final SERENA-6 PFS2 25.7 vs 19.1 months (HR 0.63) and 46% lower risk of deterioration in global health status/QOL
The ODAC record on camizestrant: a 6-3 vote against, and disagreement over whether PFS2 as designed can answer the early-switch question — ODAC voted 6-3 against recommending approval of camizestrant based on SERENA-6, with the stated takeaway that the long-term benefit of an early switch in the absence of radiographic progression is unknown and PFS2 as designed does not answer it
SERENA-6 ESR1 kinetics: ctDNA detects mutations in about 20% within the first year, with peak incidence between years 1 and 4 — Cumulative incidence of ESR1 mutations rises steadily over time, with ctDNA monitoring detecting ESR1m in about 20% within 1 year and the highest incidence between years 1-4
TNBC-DX plus TILs in stage I TNBC: 100% 5-year RFS in the high immune-signature group, but no significant discrimination overall — TNBC-DX plus TILs was evaluated in more than 100 patients with stage I TNBC, finding 100% 5-year RFS in patients with high CIG immune signature and poor outcomes with low CIG or high proliferation signature
Iza-bren hits its PFS primary endpoint in PANKU-Breast01, its fifth positive phase 3 — and advocates ask for sequencing and dose data — Iza-bren met the PFS primary endpoint at a pre-specified interim analysis of PANKU-Breast01 (BL-B01D1-306) in HR+/HER2- breast cancer, the fifth phase 3 trial to hit its primary endpoint for iza-bren

Full details below ↓

📄 What's Being Published

Manuscripts:

Systemic Therapy Considerations in Older Adults With Early-Stage Breast Cancer: A Review. — Smith Claire E et al., JAMA Oncol

This review addresses the dual risk of overtreatment and undertreatment in older patients with early breast cancer, noting that clinicians should aim to avoid overtreatment when available evidence suggests a less intensive approach may suffice for a lower-risk cancer, and/or the patient is at high risk of serious toxic effects from chemotherapy treatment, while undertreatment without consideration of the potential downsides may increase breast cancer-related mortality in older patients with higher-risk cancers. The review also catalogues current evidence across subtypes, including novel strategies such as adjuvant cyclin-dependent kinase 4/6 inhibitors in hormone receptor-positive disease and the neoadjuvant use of pembrolizumab in triple-negative breast cancer.

Clinical bottom line: With the review now circulating alongside a practical pre-chemotherapy checklist, chemotherapy decisions in adults over 70 should rest on geriatric assessment, CARG-BC toxicity risk, competing mortality, and patient goals rather than age alone; reflex undertreatment of fit older adults with high-risk TNBC should be avoided.

Read full article →

Atezolizumab in early triple-negative breast cancer: the randomized phase 3 NSABP B-59/GeparDouze trial. — Loibl Sibylle et al., Nat Med

The multicenter, multinational, double-blinded NSABP B-59/GeparDouze trial evaluated 773 patients randomized to atezolizumab and 777 to placebo added to sequential taxane-carboplatin-anthracycline-based neoadjuvant chemotherapy in stage II-III TNBC; atezolizumab did not significantly improve the primary endpoint of event-free survival (HR 0.80, 95% CI 0.062–1.03; stratified log-rank P = 0.083; 4-year EFS rates difference 3.3%), and the HR for overall survival was 0.86 (95% CI 0.62–1.19) with a 4-year benefit of 0.7%. Prespecified subgroup analyses suggested heterogeneity in EFS, with benefit of atezolizumab in patients presenting with clinical lymph node involvement (Pinteraction = 0.039), while immune-related adverse events were reported in 27.6% with atezolizumab versus 11.4% with placebo, and 196 (25.5%) patients discontinued atezolizumab versus 143 (18.8%) who discontinued placebo in the neoadjuvant phase.

Clinical bottom line: Atezolizumab should not be added to neoadjuvant chemotherapy for unselected stage II-III TNBC; any future use depends on prospective selection by nodal involvement, basal-like immune-activated subtype, or high tumor-infiltrating lymphocytes.

Read full article →

Neoadjuvant Anbenitamab and HB1801 in ERBB2-Positive Breast Cancer: A Phase 3 Randomized Clinical Trial. — Li Junjie et al., JAMA Oncol

Among 521 patients, the tpCR rate was significantly higher in the investigational group than the control group (164 patients [62.4%] vs 132 patients [51.2%]; absolute difference 11.4 [95% CI, 3.2 to 19.6] percentage points; P = .004), with benefit consistent across subgroups including hormone receptor-negative disease (76.3% vs 59.5%) and hormone receptor-positive disease (51.7% vs 44.4%). Grade 3 or 4 treatment-related adverse events occurred in 77 patients (29.3%) in the investigational group and 73 patients (28.3%) in the control group, with no treatment-related deaths.

Clinical bottom line: Substituting the biparatopic ERBB2 antibody anbenitamab plus albumin-bound docetaxel for trastuzumab, pertuzumab, and docetaxel raises tpCR by 11.4 percentage points without added grade 3–4 toxicity; because both the antibody and the taxane were swapped simultaneously, the source of the gain cannot be assigned, and survival follow-up is pending.

Read full article →

🗂 Every paper considered this week, including the ones that didn’t make it →

🗣️ What People Were Discussing This Week

How these are chosen: filtered for clinical relevance, grouped by the new development discussed, then ordered by engagement (bookmarks and reposts).

FDA grants accelerated approval to camizestrant at ctDNA-detected ESR1 emergence — the first approval triggered by molecular, not radiographic, progression

FDA granted accelerated approval to camizestrant plus a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for HR+/HER2- advanced breast cancer upon ESR1 mutation detected during AI plus CDK4/6i therapy by FDA-authorized test — described as the first approval ever driven by ctDNA rather than imaging. In SERENA-6, mPFS was 16.8 vs 9.2 months (HR 0.45), final PFS2 was 25.7 vs 19.1 months (HR 0.63), and there was a 46% lower risk of deterioration in global health status/QOL; the approval came despite an ODAC vote of 3–6 against on April 30, and carries a black box warning for QT prolongation/arrhythmia risk with OS data not yet mature. Some clinicians remain unpersuaded, stating that current SERENA-6 results do not persuade them that changing treatment for ESR1 mutation emergence without radiographic progression benefits patients given much higher cost, safety issues, and no survival benefit at this point; others frame the open question as whether there is a survival benefit to switching to an oral SERD at molecular progression rather than continuing current therapy and switching only after radiologic progression. Patient advocates welcomed the additional option while noting that insurance coverage of ctDNA screening outside of progression remains unresolved, and, because the approval is accelerated, confirmatory studies will be required to confirm the benefit of this strategy and achieve full approval.

Discussed by: @Dr_ElvinaA, @DFCI_BreastOnc, @OncBrothers, @OncBrothers, @OncoAlert, @DrChoueiri, @tmprowell, @tmprowell, @ErikaHamilton9, @GaiaGriguolo, @n8pennell, @OncoAlert, @Dr_ElvinaA, @OncoAlert

→ View representative tweet

The ODAC record on camizestrant: a 6-3 vote against, and disagreement over whether PFS2 as designed can answer the early-switch question

ODAC voted 6-3 against recommending approval of camizestrant based on SERENA-6, with the stated takeaway that the long-term benefit of an early switch in the absence of radiographic progression is unknown and PFS2 as designed does not answer it. The FDA briefing document was described as clearly outlining the reasons for the decision and how PFS2 will be interpreted, and recommended reading for drug developers and pharma. A counterargument holds that the 9.2-month control PFS does not mean "no need to act" — that it represents a window where ESR1 subclones can be intercepted before broader resistance biology beyond ESR1 mutation emerges and dominates — and that drug efficacy evidence (characterized as clearly established, with PFS 16 vs 9.2 months, HR approximately 0.44) and strategy evidence are two separate questions; patient advocates added that the ODAC discussion was an important reminder that encouraging data is only part of the story, and what matters most is whether a treatment change will truly improve outcomes in ways that are meaningful for patients.

Discussed by: @ErikaHamilton9, @ErikaHamilton9, @LoiSher, @GIMedOnc, @JaniceTNBCmets

→ View representative tweet

SERENA-6 ESR1 kinetics: ctDNA detects mutations in about 20% within the first year, with peak incidence between years 1 and 4

New data from SERENA-6 show that the cumulative incidence of ESR1 mutations rises steadily over time: ctDNA monitoring detected ESR1 mutations in approximately 20% of patients within 1 year, with incidence numerically highest during 12–48 months of first-line AI plus CDK4/6 inhibitor therapy. The practical question this raises is how frequently and for how long serial ctDNA sampling must be performed to make a monitoring strategy feasible given that emergence peaks between years 1 and 4.

Discussed by: @PTarantinoMD, @ErikaHamilton9

→ View representative tweet

TNBC-DX plus TILs in stage I TNBC: 100% 5-year RFS in the high immune-signature group, but no significant discrimination overall

TNBC-DX plus TILs was evaluated in more than 100 patients with stage I TNBC, and in a dataset of 253 patients the overall prognosis was excellent — 3-year RFS 95.0% and 3-year OS 97.9% — with numerical signals in the immune-high subgroup: 100% 3-year RFS in the highest TNBC-DX CIG quartile and 97% 3-year RFS with sTILs greater than 20%, compared with 83% 3-year RFS in patients with a high proliferation score. However, neither TNBC-DX nor sTIL category significantly differentiated RFS, and only 18 recurrences occurred, so these data do not yet justify omitting chemotherapy.

Discussed by: @stolaney1, @stolaney1

→ View representative tweet

Iza-bren hits its PFS primary endpoint in PANKU-Breast01, its fifth positive phase 3 — and advocates ask for sequencing and dose data

Iza-bren (Yizekang®) met the PFS primary endpoint at a pre-specified interim analysis of PANKU-Breast01 (BL-B01D1-306) in HR+/HER2- breast cancer, making it the fifth phase 3 trial to hit its primary endpoint for iza-bren. With more ADCs carrying similar targets or payloads in development, oncologists and patient advocates are calling for sequencing and dose-optimization data to establish which drug, for whom, in what order, and at what dose.

Discussed by: @stolaney1, @JaniceTNBCmets

→ View representative tweet

I-SPY2: cemiplimab plus fianlimab roughly doubles neoadjuvant pCR in high-risk ERBB2-negative disease, at the cost of 21% adrenal insufficiency

In I-SPY2, adding dual checkpoint blockade with cemiplimab plus fianlimab to neoadjuvant chemotherapy increased pCR rates overall (44% vs 21%), in TNBC (53% vs 29%), and in HR+/HER2- disease (36% vs 14%), with responses particularly strong in triple-negative and immune-signature-positive tumors. Against this efficacy signal, adrenal insufficiency occurred in 21% of participants, posing a direct trade-off between pathologic response and immune-related toxicity in the curative setting where the durability of pCR gains and the appropriate biomarker for patient selection remain undefined.

Discussed by: @Dr_ElvinaA, @OncoAlert, @OncoAlert

→ View representative tweet

🔥 Top Ranked Tweets

Dee Sparacio @womenofteal

RT @DrRishabhOnco: 🚨 NEW ASCO 2026 Living Guideline: HR+/HER2− Stage I–III Breast Cancer

A few recommendations worth bookmarking 👇

🔹 Endocrine therapy remains the backbone of systemic treatment.

🔹 Low ER expression (<10%), stage II–III: neoadjuvant treatment may follow a TNBC-style regimen with taxane + carboplatin + anthracycline + pembrolizumab.

🔹 Neoadjuvant CDK4/6 inhibitors: insufficient evidence for routine use.

🔹 Adjuvant CDK4/6:
• Abemaciclib × 2 y for monarchE-eligible patients
• Ribociclib × 3 y for NATALEE-eligible patients

📌 ASCO suggests using absolute risk to guide CDK4/6 treatment:

25% 10-y breast cancer mortality risk → recommend
10–25% → consider
<10% → generally do not recommend

⭐ If eligible for both, the Panel favors abemaciclib over ribociclib, citing shorter treatment duration + demonstrated OS benefit.

🧬 High-risk germline BRCA1/2 or PALB2 → offer 1 year adjuvant olaparib; ASCO prioritizes olaparib over CDK4/6 inhibition when both apply.

Verdict: Early HR+/HER2− breast cancer management is becoming increasingly risk-adapted, genomically informed, and targeted.

@ASCO @OncoAlert #BreastCancer #Oncology

🔖 87 ❤️ 124 🔁 61 👁 7,922